Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06687876 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

Study acronym: MEMENTO
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Dec 2024 to Mar 9, 2025
    v3
  2. Eligibility criteria revised
    • Study description revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
Trial Details
NCT Number NCT06687876
Lead Sponsor Amsterdam UMC, location VUmc
Collaborators: Cancer Center Amsterdam Research Foundation
Conditions
(from sponsor)		 Oesophageal Adenocarcinoma, Tumor Microenvironment
Related terms Adenocarcinoma, Adenocarcinoma Of Esophagus, Esophageal Neoplasms
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov